Related Experiment Video
Updated: Aug 1, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy
J L Good1, M Chehrenama, R F Mayer
1University of Maryland School of Medicine, Department of Neurology, Baltimore 21201, USA.
Neurology
|December 17, 1998
Summary
Monthly pulse intravenous cyclophosphamide (IVCY) shows promise for treating chronic inflammatory demyelinating neuropathy (CIDP). Most patients achieved remission, indicating potential benefits for this debilitating neurological condition.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Chronic inflammatory demyelinating neuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
- Current CIDP treatments can have significant side effects or limited efficacy.
- Novel therapeutic strategies are needed for effective CIDP management.
Purpose of the Study:
- To evaluate the efficacy and safety of monthly pulse intravenous cyclophosphamide (IVCY) in patients with CIDP.
- To assess the remission rates and adverse events associated with this treatment regimen.
Main Methods:
- A case series of fifteen CIDP patients treated with monthly IVCY for up to 6 months.
- Monitoring of patient response, including remission status and disease progression.
- Documentation of treatment-related complications.
Main Results:
- Eleven out of fifteen patients achieved complete remission.
- Only one patient experienced disease worsening during the study period.
- Common adverse events included nausea, vomiting, anemia, and hair loss.
Conclusions:
- Monthly pulse IVCY appears to be a beneficial treatment for CIDP.
- The observed efficacy suggests that IVCY warrants further investigation in controlled clinical trials.
- This approach may offer a new therapeutic option for CIDP patients.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:26Peripheral Artery Disease IV: Nursing Management
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
01:23Peripheral Artery Disease V: Postoperative Nursing Management
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...